Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|August 30, 2024

Combining Abiraterone with Steroids

Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD

This discussion explores the differences in the effects of abiraterone formulations when combined with prednisone or methylprednisolone.

Episodes in this series

2 KOLs are featured in this series.

EP. 1 Expert Perspective on the Expanding Treatment Landscape in mCRPC

2 KOLs are featured in this series.

EP. 2 The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC

2 KOLs are featured in this series.

EP. 3 Management of Comment Adverse Effects Associated with mCRPC Therapies

2 KOLs are featured in this series.

EP. 4 Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

2 KOLs are featured in this series.

EP. 5 Overview of Abiraterone and the Differences Between Formulations

2 KOLs are featured in this series.

EP. 6 Combining Abiraterone with Steroids

2 KOLs are featured in this series.

EP. 7 The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

2 KOLs are featured in this series.

EP. 8 Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

2 KOLs are featured in this series.

EP. 9 Dosing and Administration Considerations for Abiraterone Formulations

2 KOLs are featured in this series.

EP. 10 Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC

2 KOLs are featured in this series.

EP. 11 Future Directions in mCRPC

How do these formulations differ when combined with prednisone or methylprednisolone?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.